Saturday 17 October 2026
Export ELAN’s income statement to Excel — free account
Elanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 450.0%, free cash flow grew 35.6% and total debt fell 6.91%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
23.55
0.01
+0.04%
Follow ELAN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 5 | 6 |
+8 more TTM periods Free account |
| (2.98%) | (3.77%) | (3.67%) | 0.54% | ||
| (1.46%) | (1.85%) | (1.79%) | 0.27% | ||
ROIC |
0.51% | 0.35% | 0.09% | 1.21% | |
Return on Tangible Assets |
(5.93%) | (7.30%) | (7.09%) | 1.05% | |
Average Days of Receivables |
83.76 | 86.08 | 72.77 | 77.52 | |
Free Cash Flow per Share |
0.76 | 0.63 | 0.57 | 0.74 | |
Free Cash Flow |
379.00 | 315.00 | 284.00 | 368.00 | |
Capital Expenditures |
(238.00) | (262.00) | (276.00) | (261.00) | |
| Other line items | |||||
Cash ROIC |
3.43% | 2.88% | 2.56% | 3.26% | |
Accounts Receivable Turnover |
4.45 | 4.42 | 5.16 | 4.89 | |
Accounts Payable Turnover |
5.64 | 6.27 | 6.39 | 6.77 | |
Inventory Turnover |
1.30 | 1.33 | 1.28 | 1.24 | |
Average Days of Payables |
69.55 | 61.75 | 63.30 | 62.13 | |
Days of Inventory on Hand |
288.12 | 285.00 | 298.78 | 301.46 | |
Tax Rate |
0.20 | 0.23 | 0.04 | (3.25) | |
Research and Development Expense of Revenue |
7.39% | 7.58% | 7.80% | 7.75% | |
Selling, General and Administrative Expense of Revenue |
30.26% | 30.04% | 30.33% | 30.32% | |
Share Based Compensation of Revenue |
1.47% | 1.51% | 1.44% | 1.46% | |
Interest Coverage |
0.33 | 0.24 | 0.07 | 1.07 | |
Operating CF/Net income |
(3.10) | (2.38) | (2.41) | 17.47 | |
Depreciation/Fixed assets |
0.49 | 0.50 | 0.48 | 0.48 | |
Capex/Depreciation |
(0.34) | (0.38) | (0.41) | (0.39) | |
Revenue per Share |
10.05 | 9.83 | 9.50 | 9.24 | |
Operating CF per Share |
1.24 | 1.16 | 1.13 | 1.27 | |
Capex per Share |
(0.48) | (0.53) | (0.56) | (0.53) | |
Capex to Sales |
0.05 | 0.05 | 0.06 | 0.06 |
Columns are period end dates